Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VRDN vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRDN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

VRDN Overall Winner 6-Pillar Tally: VRDN 4 – 1 ZBIO (1 Tie) Matrix Metrics: VRDN 7 – 2 ZBIO

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VRDN carries a Unified Composite Score of 36.8/100 (SELL) at $29.80 (1.0x Forward P/E, -1781.4% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. -2747.5% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRDN vs ZBIO
VRDN NASDAQ Head-to-Head Winner
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$29.80
-3.47% 1D
Market Cap $3.5B
TTM Revenue $26M
Forward P/E 1.0x
Beta / 30D Vol 1.13β · 65% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 72
RSI-14: 72.2 · SMA20: $26.61 · SMA50: $22.89
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (VRDN 4 – 1 ZBIO)

Columns: Metric · VRDN · ZBIO
1. Valuation Multiples VRDN
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue 135.9x N/M
2. Growth & Scale VRDN
Revenue Growth (YoY) -63.5% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $26M $11M
Market Cap $3.5B $1.9B
3. Profitability & Quality VRDN
Gross Margin N/A N/A
Operating Margin -1781.4% -2747.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -83.7% -265.1%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$353M -$273M
Cash Flow Margin N/A N/A
Net Cash / Leverage $70M Net Debt (0.42x D/E) $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRDN
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 70.7% (16th %ile) 103.9% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRDN (7) vs ZBIO (2)
Institutional Metric VRDN ZBIO Criterion Row Edge
Market Capitalization
Scale
$3.5B $1.9B Larger Scale VRDN
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple VRDN
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple VRDN
Revenue Growth (YoY)
Growth
-63.5% -100.0% Higher Growth VRDN
Operating Margin (TTM)
Profitability
-1781.4% -2747.5% Higher Margin VRDN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-83.7% -265.1% Higher ROE VRDN
52-Week Range Position
Momentum
79% ($13–$34) 46% ($14–$45) Stronger Trend VRDN
Beta / 30D Volatility
Risk Regime
1.13β · 65% Vol 1.16β · 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$26M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 135.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$353M ($70M Net Debt (0.42x D/E)) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VRDN +44.15 pp
VRDN: +56.59% · ZBIO: +12.44%
3M Horizon VRDN +37.0 pp
VRDN: +24.53% · ZBIO: -12.47%
6M Horizon VRDN +19.92 pp
VRDN: +85.09% · ZBIO: +65.17%
1Y Horizon VRDN +26.28 pp
VRDN: +4.6% · ZBIO: -21.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VRDN Revenue ZBIO Revenue VRDN Op. Margin ZBIO Op. Margin Margin Leader
FY2018 $10M N/A -394.5% N/A VRDN
FY2019 $0M N/A -941.0% N/A VRDN
FY2020 $0M N/A -10512.4% N/A VRDN
FY2021 $0M N/A -2690.8% N/A VRDN
FY2022 $0M N/A -7579.2% N/A VRDN
FY2023 $0M $50M -81035.0% -74.3% ZBIO
FY2024 $0M $10M -99018.2% -3277.8% ZBIO
FY2025 $70M $10M -512.9% -3830.6% VRDN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRDN SURGE
5d in phase · OBV ACCUMULATION
Current IV 70.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRDN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -1781.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRDN vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VRDN carries a Unified Composite Score of 36.8/100 (SELL) at $29.80 (1.0x Forward P/E, -1781.4% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. -2747.5% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY). Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRDN leads the Growth & Scale pillar: VRDN posts -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VRDN cumulative revenue shifted +600.0% while ZBIO shifted -80.0%. In operating R&D and SG&A reinvestment, VRDN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

VRDN screens cheaper on headline valuation multiples. VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 135.9x EV/Revenue (unreported FCF margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRDN (-83.7% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VRDN carries 70.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.13β · 65% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.